rs112513025 - STAU1 - DDX27

Magnitude 2.0 · 1 study on file

Reported associations

• Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD. - Respiratory medicine (2020) · Condreay LD, Qu XA, Anderson J, Compton C, Ghosh S · PubMed 31299468

  No studies have investigated genetic effects on quality of life (QoL) measurements like improvements in the St George's Respiratory Questionnaire (SGRQ) scores for chronic obstructive pulmonary disease treatments with fluticasone propionate/salmeterol (FSC). Therefore, in addition to testing genetic effects on change from baseline in trough forced expiratory volume in 1 s (FEV ), genetic associations that may predict SGRQ response to FSC treatment were investigated in this analysis. This post hoc exploratory genome-wide genetic analysis included subjects from 10 clinical trials: NCT01772134, NCT01772147, NCT00633217, NCT01817764, NCT01879410, NCT01822899, NCT01323621, NCT01342913, NCT01323634, and NCT01706328. The Genetics Analysis Population (subjects who provided written consent, a blo

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.